<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511433305</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511433305</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>National estimate of multiple sclerosis incidence in France (2001–2007)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Fromont</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511433305">1</xref>
<xref ref-type="aff" rid="aff2-1352458511433305">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Binquet</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511433305">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sauleau</surname><given-names>EA</given-names></name>
<xref ref-type="aff" rid="aff4-1352458511433305">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fournel</surname><given-names>I</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511433305">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Despalins</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511433305">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rollot</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511433305">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Weill</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff5-1352458511433305">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Clerc</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff6-1352458511433305">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bonithon-Kopp</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511433305">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Moreau</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511433305">1</xref>
<xref ref-type="aff" rid="aff2-1352458511433305">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511433305"><label>1</label>Department of Neurology, University Hospital of Dijon, France</aff>
<aff id="aff2-1352458511433305"><label>2</label>Burgundy University, Centre of Epidemiology of the Populations EA 4184, France</aff>
<aff id="aff3-1352458511433305"><label>3</label>INSERM, CIE1, France; Dijon University Hospital, Clinical Investigation Centre – Clinical Epidemiology / Clinical Trials, France; Burgundy University, France</aff>
<aff id="aff4-1352458511433305"><label>4</label>Strasbourg University Hospitals, Public Health Department, Biostatistics and Methodology Unit, France</aff>
<aff id="aff5-1352458511433305"><label>5</label>French Public Health Insurance, Paris, France</aff>
<aff id="aff6-1352458511433305"><label>6</label>French Public Health Insurance, Direction of the Medical Department, Dijon, France</aff>
<author-notes>
<corresp id="corresp1-1352458511433305">Professor T Moreau, Department of Neurology, 3 rue du Faubourg Raines 21000 Dijon, France. Email: <email>thibault.moreau@chu-dijon.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>8</issue>
<fpage>1108</fpage>
<lpage>1115</lpage>
<history>
<date date-type="received">
<day>18</day>
<month>8</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>27</day>
<month>10</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>25</day>
<month>11</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>11</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1352458511433305">
<title>Background:</title>
<p>In France, the incidence of multiple sclerosis (MS) is not well known, and MS is one of the 30 long-term illnesses for which patients are covered for 100% of their health care costs.</p>
</sec>
<sec id="section2-1352458511433305">
<title>Objective:</title>
<p>To estimate the incidence of MS in France and its geographic variations.</p>
</sec>
<sec id="section3-1352458511433305">
<title>Methods:</title>
<p>We estimated the national rate for notification of MS to the main French health insurance system, and its confidence interval (CI), between November 2000 and October 2007, which covers 87% of the population. We analysed geographic variations using a Bayesian approach.</p>
</sec>
<sec id="section4-1352458511433305">
<title>Results:</title>
<p>Between November 2000 and October 2007, among a covered population of 52,449,871, some 28,682 individuals were registered as having MS. After age standardization according to the European population, the notification rate for MS was 6.8 per 100,000 (6.7–6.9), 9.8 (9.7–10.0) in women and 3.7 (3.6–3.8) in men. When the under-notification rate (11.5% and 29%) was taken into account, the notification rate per 100,000 inhabitants was estimated between 7.6 and 8.8. The notification rate was higher in north-eastern France, and lower on the Atlantic coast and in the Alps as well as on both sides of the Rhône River.</p>
</sec>
<sec id="section5-1352458511433305">
<title>Conclusions:</title>
<p>This study, conducted on a representative French population, provides for the first time national estimates of MS incidence between November 2000 and October 2007.</p>
</sec>
</abstract>
<kwd-group>
<kwd>multiple sclerosis</kwd>
<kwd>incidence</kwd>
<kwd>geographical variations</kwd>
<kwd>France</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section6-1352458511433305" sec-type="intro">
<title>Introduction</title>
<p>In France, as in most European countries, the incidence of multiple sclerosis (MS) is not well known. Most national studies have so far focused on MS prevalence which, unlike incidence, can be estimated from cross-sectional studies.<sup><xref ref-type="bibr" rid="bibr1-1352458511433305">1</xref>,<xref ref-type="bibr" rid="bibr2-1352458511433305">2</xref></sup> Prevalence based on the overall number of patients with MS is a complex indicator, difficult to interpret, as it depends on patients’ life expectancy and on the earliness of diagnosis, which may vary according to health care systems. In contrast, incidence is based only on the number of new cases diagnosed in the population, and combining incidence with geographic, environmental and socioeconomic data may help researchers to formulate new aetiological hypotheses.</p>
<p>Most studies that have estimated the incidence of MS in Europe were performed either in Scandinavian countries,<sup><xref ref-type="bibr" rid="bibr3-1352458511433305">3</xref><xref ref-type="bibr" rid="bibr4-1352458511433305"/>-<xref ref-type="bibr" rid="bibr5-1352458511433305">5</xref></sup> in Great Britain<sup><xref ref-type="bibr" rid="bibr6-1352458511433305">6</xref></sup> or in southern Europe (Patras (Greece),<sup><xref ref-type="bibr" rid="bibr7-1352458511433305">7</xref></sup> Sicily,<sup><xref ref-type="bibr" rid="bibr8-1352458511433305">8</xref>,<xref ref-type="bibr" rid="bibr9-1352458511433305">9</xref></sup> and Sardinia).<sup><xref ref-type="bibr" rid="bibr10-1352458511433305">10</xref></sup> They were mainly performed on a regional scale, thus reducing their ability to be generalized. Only two studies, in Great Britain<sup><xref ref-type="bibr" rid="bibr6-1352458511433305">6</xref></sup> and in Iceland,<sup><xref ref-type="bibr" rid="bibr11-1352458511433305">11</xref></sup> were performed on a national scale. However, as incidence may change according to latitude, the results cannot be extrapolated to France overall.</p>
<p>Most of the previously published French studies on MS incidence were also performed on a city or regional scale.<sup><xref ref-type="bibr" rid="bibr12-1352458511433305">12</xref><xref ref-type="bibr" rid="bibr13-1352458511433305"/><xref ref-type="bibr" rid="bibr14-1352458511433305"/>-<xref ref-type="bibr" rid="bibr15-1352458511433305">15</xref></sup> In addition, they were performed during periods when disease-modifying treatments (DMT) became available and/or changes in imaging techniques occurred. This may have induced an artificial increase in MS incidence. Moreover, we previously showed geographical disparities in the prevalence of MS in France, with a higher prevalence in north-eastern administrative areas (‘départements’).<sup><xref ref-type="bibr" rid="bibr2-1352458511433305">2</xref></sup> Since prevalence and incidence are related, disparities in MS incidence from one ‘département’ to another are to be expected.</p>
<p>Given the lack of accurate national incidence data, we decided to estimate the incidence of MS in France and variations occurring in the 96 French ‘départements’ between 2001 and 2007 using a single source of data, the Caisse Nationale d’Assurance Maladie des Travailleurs Salariés (CNAMTS), which covers 87% of the French population.</p>
</sec>
<sec id="section7-1352458511433305" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section8-1352458511433305">
<title>Setting</title>
<p>This study was conducted using CNAMTS data collected between November 2000 and October 2007 in metropolitan France (including Corsica) located between latitudes 42° and 51° north. France numbered 60,028,292 inhabitants in 2004 (<ext-link ext-link-type="uri" xlink:href="http://www.insee.fr">www.insee.fr</ext-link>) and covers an area of 535,280 km<sup>2</sup> divided into 96 ‘départements’ which are grouped into 22 regions. The population density of these French administrative areas shows large variations (from 15 inhabitants/km<sup>2</sup> in Lozère to 20,569 inhabitants/km<sup>2</sup> in Paris). Age distribution also varies (the proportion of inhabitants aged over 60years ranges from 16.5% in Paris to 30% in Lozère).</p>
</sec>
<sec id="section9-1352458511433305">
<title>Data sources</title>
<p>In France, MS is one of the 30 long-term illnesses (Affections de Longue Durée, ALD) for which patients are covered for 100% of their health care costs. Once the diagnosis of MS has been established by a neurologist according to current validated diagnosis criteria, a request is sent to the health insurance system and validated by a CNAMTS doctor. All the data relative to the request for ALD status are systematically collected by the CNAMTS, which covers salaried employees in the private sector, civil and non-civil servants and their families, hence covering 87% of the French population.</p>
<p>We used the data collected by the CNAMTS for patients with MS, residing in metropolitan France (including Corsica) who were granted ALD status for MS between November 2000 and October 2007. These data included dates of birth and request for ALD status, gender, and ‘département’ of residence. The period between November 2000 and October 2007 was chosen to avoid any modifications in ALD notification due to the launch of a costly DMT in 1995 which led to an overestimation of MS cases. Indeed, a preliminary analysis of new requests for ALD status for MS collected between 1995 and 2007 showed that requests increased much more before 2000 (11.4% annual increase before 2000 versus 1.9% since 2001). In addition, the annual increase in ALD requests showed large variations between regions from 1995 to 2000 (<italic>p</italic> for interaction year–region &lt; 10<sup>−4</sup>), but could be considered similar afterwards (<italic>p</italic> for interaction = 0.18).</p>
<p>The CNAMTS provided coverage figures for each year, stratified by gender, 5-year age groups, and ‘département’. In accordance with French law, this study was approved by the National Commission of data processing and civil liberties.</p>
</sec>
<sec id="section10-1352458511433305">
<title>Statistical analysis</title>
<sec id="section11-1352458511433305">
<title>Estimation of national incidence</title>
<p>Crude and standardized annual MS incidence rates in the CNAMTS population were estimated using the number of ALD requests for MS as an approximation of the number of new MS cases. Annual MS incidence in the entire French population was estimated by multiplying the annual number of ALD requests among persons covered by the CNAMTS by the inverse of the coverage rate of this insurance system calculated by gender, 5-year age category and ‘département’. These annual incidence rates were then standardized on the European and world populations.</p>
<p>A previous study performed in the Haute-Garonne ‘département’ (in south-western France) showed that the number of MS cases identified through the entire public health insurance system alone could underestimate true incidence by between 11.5–29%.<sup><xref ref-type="bibr" rid="bibr16-1352458511433305">16</xref></sup> These percentages represent the lower and upper bounds of the underestimation due to the use of a single source. Thus these figures were also taken into account.</p>
</sec>
<sec id="section12-1352458511433305">
<title>Study of geographical disparities</title>
<sec id="section13-1352458511433305">
<title>Standardized incidence ratio</title>
<p>In each administrative area, we calculated the standardized incidence ratio (SIR). This is the ratio between the observed number of new patients with MS according to the CNAMTS database, and the expected number<sup><xref ref-type="bibr" rid="bibr17-1352458511433305">17</xref></sup> obtained by multiplying the gender and age-specific incidence in the overall CNAMTS population by the number of people in each age and gender stratum of the area.</p>
</sec>
<sec id="section14-1352458511433305">
<title>Spatial model</title>
<p>We tested the existence of incidence variations between administrative areas using the Potthoff–Whittinghill test.<sup><xref ref-type="bibr" rid="bibr18-1352458511433305">18</xref></sup> We also tested for a possible spatial correlation using the Moran test, since contiguous areas may not be independent.<sup><xref ref-type="bibr" rid="bibr19-1352458511433305">19</xref></sup> Depending on the results of these tests, we planned to use different approaches. If the Potthoff–Whittinghill test was not significant, the SIR in different areas could be considered equal to a constant and the national incidence considered a valid estimation for all ‘départements’. If the Moran test was not significant, each ‘département’ could be considered independently from its closest neighbours and a classical Poisson model could be applied. If both tests were significant, a hierarchical Bayesian Poisson model<sup><xref ref-type="bibr" rid="bibr20-1352458511433305">20</xref></sup> was applied as it can be used to estimate the relative risk (RR) in the ‘département’ compared with the mean value for the population overall, while accounting for spatial autocorrelation and adjusting for gender and age. The spatial effect was modelled by using successively (i) latitude and longitude of each ‘département’ centroid with no transformations; (ii) conditional autoregressive modelling; (iii) geokriging; and (iv) geospline. Models were compared using the Deviance Information Criterion (DIC), a Bayesian version of the Akaike criterion.<sup><xref ref-type="bibr" rid="bibr21-1352458511433305">21</xref></sup> Posterior distributions of RRs were obtained by Monte Carlo Markov chain sampling techniques. More or less informative parameters for hyperpriors were compared, and the model leading to the best fit (i.e. the lowest DIC) was retained. We systematically tested the interaction between the geographical area and the other available variables, i.e. age (&lt; 45 years, ≥ 45 years), gender and year of ALD request. In order to control the impact of multiple testing, a <italic>p</italic>-value below 0.016 was considered significant for these tests.</p>
</sec>
<sec id="section15-1352458511433305">
<title>Disease mapping</title>
<p>If no spatial autocorrelation was detected, a map of SIRs was established. The SIRs of the 96 French administrative areas were classified into three groups: incidence significantly (i) lower or (ii) higher than the mean national level, or (iii) not different. In the opposite case when an autocorrelation was significant, a map of smoothed RRs was established to visualize the geographical distribution of MS incidence. Smoothed RR estimates were also classified into three groups according to their posterior distribution: (i) 95% of the posterior distribution below 1, indicating an area with a lower incidence than the mean national incidence level; (ii) 95% of the posterior distribution above 1, indicating an area with a higher incidence than the mean national level; and (iii) other cases.</p>
<p>We used R 9.2.1 (<ext-link ext-link-type="uri" xlink:href="http://cran.univ-lyon1.fr/">http://cran.univ-lyon1.fr/</ext-link>) to calculate Moran and Potthoff–Whittinghill tests, Philcarto V5.05 (http://philcarto.free.fr) for mapping, SAS to prepare the data for Bayesian analyses and finally BayesX (<ext-link ext-link-type="uri" xlink:href="http://www.stat.uni-muenchen.de/bayesX">http://www.stat.uni-muenchen.de/bayesX</ext-link>) to fit Poisson models.</p>
</sec>
</sec>
</sec>
</sec>
<sec id="section16-1352458511433305" sec-type="results">
<title>Results</title>
<sec id="section17-1352458511433305">
<title>Description of the population</title>
<p>Between November 2000 and October 2007, 28,682 new cases of MS were notified to the CNAMTS and obtained an ALD status for MS. The female to male ratio was 2.7 (20,923 women (73%) versus 7759 men (27%)). The crude incidence rates by gender and age groups at the time of ALD request are shown in <xref ref-type="table" rid="table1-1352458511433305">Table 1</xref>. Most ALD requests (54%) were granted between 25 and 45 years old.</p>
<table-wrap id="table1-1352458511433305" position="float">
<label>Table 1.</label>
<caption>
<p>Mean annual standardized incidence of multiple sclerosis by age group in France (2001–2007: standardization on the French population).</p>
</caption>
<graphic alternate-form-of="table1-1352458511433305" xlink:href="10.1177_1352458511433305-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Age group</th>
<th align="left" colspan="2">Covered by the CNAMTS<sup><xref ref-type="table-fn" rid="table-fn1-1352458511433305">†</xref></sup><hr/></th>
<th align="left" rowspan="2">Number of ALDs for MS</th>
<th align="center" colspan="2">Overall<hr/></th>
<th align="center" colspan="2">Men<hr/></th>
<th align="center" colspan="2">Women<hr/></th>
</tr>
<tr>
<th align="left">n</th>
<th align="left">%<xref ref-type="table-fn" rid="table-fn1-1352458511433305">*</xref></th>
<th align="left">MS Standardized incidence</th>
<th align="left">[95% confidence interval]</th>
<th align="left">MS Standardized incidence</th>
<th align="left">[95% confidence interval]</th>
<th align="left">MS Standardized incidence</th>
<th align="left">[95% confidence interval]</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14</td>
<td>9,677,177</td>
<td>86.7</td>
<td>10</td>
<td>0.02</td>
<td>[0.01–0.02]</td>
<td>0.017</td>
<td>[0.01–0.02]</td>
<td>0.02</td>
<td>[0.01–0.026]</td>
</tr>
<tr>
<td>15-24</td>
<td>7,139,097</td>
<td>91.2</td>
<td>383</td>
<td>0.69</td>
<td>[0.67–0.72]</td>
<td>0.37</td>
<td>[0.34–0.4]</td>
<td>0.99</td>
<td>[0.94–1.04]</td>
</tr>
<tr>
<td>25-34</td>
<td>7,804,708</td>
<td>96.4</td>
<td>1038</td>
<td>1.78</td>
<td>[1.74–1.82]</td>
<td>1.02</td>
<td>[0.97–1.06]</td>
<td>2.48</td>
<td>[2.41–2.55]</td>
</tr>
<tr>
<td>35-44</td>
<td>7,805,979</td>
<td>89.8</td>
<td>1185</td>
<td>2.18</td>
<td>[2.13–2.23]</td>
<td>1.19</td>
<td>[1.14–1.24]</td>
<td>3.08</td>
<td>[3–3.16]</td>
</tr>
<tr>
<td>45-54</td>
<td>7,196,207</td>
<td>85.5</td>
<td>928</td>
<td>1.79</td>
<td>[1.75–1.84]</td>
<td>1.04</td>
<td>[0.99–1.09]</td>
<td>2.45</td>
<td>[2.38–2.52]</td>
</tr>
<tr>
<td>55-64</td>
<td>5,387,576</td>
<td>85.1</td>
<td>377</td>
<td>0.73</td>
<td>[0.7–0.76]</td>
<td>0.46</td>
<td>[0.42–0.49]</td>
<td>0.98</td>
<td>[0.94–1.03]</td>
</tr>
<tr>
<td>65-74</td>
<td>4,020,591</td>
<td>78.5</td>
<td>139</td>
<td>0.29</td>
<td>[0.27–0.31]</td>
<td>0.18</td>
<td>[0.16–0.2]</td>
<td>0.4</td>
<td>[0.37–0.43]</td>
</tr>
<tr>
<td>75 +</td>
<td>3,418,533</td>
<td>71</td>
<td>37</td>
<td>0.08</td>
<td>[0.07–0.09]</td>
<td>0.05</td>
<td>[0.04–0.06]</td>
<td>0.12</td>
<td>[0.1–0.13]</td>
</tr>
<tr>
<td>Total France</td>
<td>52,449,871</td>
<td>86.7</td>
<td>4097</td>
<td>7.6</td>
<td>[7.5–7.6]</td>
<td>4.3</td>
<td>[4.2–4.4]</td>
<td>10.5</td>
<td>[10.3–10.6]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458511433305">
<label>*</label>
<p>percentage of people in the general population covered by the CNAMTS ; <sup>†</sup> mean estimate for the period 2001–2007.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section18-1352458511433305">
<title>French national estimate of MS incidence</title>
<p>The annual mean incidence rates of MS notified to the CNAMTS between November 2000 and October 2007 standardized on the European population, were 6.8 per 100,000 people, 9.8 for women and 3.7 for men. After standardization on the world population, incidence rates were 6.6 per 100,000 people, 9.5 for women and 3.8 for men. The standardized incidence of new MS cases declared to the CNAMTS adjusted by age and gender are shown in <xref ref-type="fig" rid="fig1-1352458511433305">Figure 1</xref>.</p>
<fig id="fig1-1352458511433305" position="float">
<label>Figure 1.</label>
<caption>
<p>Standardized incidence of new multiple sclerosis cases in France between 2001–2007 declared to the CNAMTS adjusted by age and gender.</p>
</caption>
<graphic xlink:href="10.1177_1352458511433305-fig1.tif"/>
</fig>
<p>When the coverage rates of the CNAMTS and the 11.5% under-notification rate (due to the fact that we used only one source of information) were taken into account, the overall French MS standardized incidence rate per 100,000 inhabitants was estimated at 7.6 when both genders were combined, 4.2 in men, and 11.0 in women. With an under-notification rate of 29%, the incidence per 100,000 was 8.8 when both genders were combined, 4.8 in men and 12.7 in women (see <xref ref-type="table" rid="table2-1352458511433305">Table 2</xref>).</p>
<table-wrap id="table2-1352458511433305" position="float">
<label>Table 2.</label>
<caption>
<p>Mean annual multiple sclerosis numbers and rates in France (2001–2007).</p>
</caption>
<graphic alternate-form-of="table2-1352458511433305" xlink:href="10.1177_1352458511433305-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th colspan="3"/>
<th align="center" colspan="9">Overall French population<hr/></th>
</tr>
<tr>
<th/>
<th colspan="6"/>
<th align="center" colspan="6">Estimations accounting for the CNAMTS<sup><xref ref-type="table-fn" rid="table-fn2-1352458511433305">*</xref></sup> coverage rate and the under-notification rate of MS<sup><xref ref-type="table-fn" rid="table-fn2-1352458511433305">*</xref></sup> cases</th>
</tr>
<tr>
<th/>
<th align="center" colspan="3">CNAMTS<sup><xref ref-type="table-fn" rid="table-fn2-1352458511433305">*</xref></sup><hr/></th>
<th align="center" colspan="3">Estimations accounting for the CNAMTS<sup><xref ref-type="table-fn" rid="table-fn2-1352458511433305">*</xref></sup> coverage rate<hr/></th>
<th align="left" colspan="3">11.5%<sup><xref ref-type="table-fn" rid="table-fn3-1352458511433305">**</xref></sup><hr/></th>
<th align="left" colspan="3">29.0%<sup><xref ref-type="table-fn" rid="table-fn3-1352458511433305">**</xref></sup><hr/></th>
</tr>
<tr>
<th/>
<th align="left">Total</th>
<th align="left">Women</th>
<th align="left">Men</th>
<th align="left">Total</th>
<th align="left">Women</th>
<th align="left">Men</th>
<th align="left">Total</th>
<th align="left">Women</th>
<th align="left">Men</th>
<th align="left">Total</th>
<th align="left">Women</th>
<th align="left">Men</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Mean annual number of MS<sup><xref ref-type="table-fn" rid="table-fn2-1352458511433305">*</xref></sup> cases per year</bold></td>
<td>4097</td>
<td>2989</td>
<td>1108</td>
<td>4536</td>
<td>3274</td>
<td>1262</td>
<td>5058</td>
<td>3651</td>
<td>1407</td>
<td>5851</td>
<td>4224</td>
<td>1628</td>
</tr>
<tr>
<td><bold>Mean annual population (millions)</bold></td>
<td>52.4</td>
<td>27.3</td>
<td>25.1</td>
<td>60.5</td>
<td>31.1</td>
<td>29.3</td>
<td>60.5</td>
<td>31.2</td>
<td>29.3</td>
<td>60.5</td>
<td>31.2</td>
<td>29.3</td>
</tr>
<tr>
<td><bold>Mean crude incidence per 100,000 population [95% confidence interval]</bold></td>
<td>7.8 [7.7–7.9]</td>
<td>10.9 [10.8–11.1]</td>
<td>4.4 [4.3–4.5]</td>
<td>7.5 [7.4–7.6]</td>
<td>10.5 [10.4–10.6]</td>
<td>4.3 [4.2–4.4]</td>
<td>8.4 [8.3–8.5]</td>
<td>11.7 <break/>[11.6–11.9]</td>
<td>4.8 [4.7–4.9]</td>
<td>9.7 [9.6–9.8]</td>
<td>13.6 [13.4–13.7]</td>
<td>5.6 [5.5–5.7]</td>
</tr>
<tr>
<td><bold>Standardized incidence rates per 100,000 world population<sup><xref ref-type="table-fn" rid="table-fn4-1352458511433305">***</xref></sup> [95% confidence interval]</bold></td>
<td>6.6 [6.6–6.7]</td>
<td>9.5 <break/>[9.4–9.7]</td>
<td>3.8 [3.7–3.8]</td>
<td>6.7 [6.6–6.7]</td>
<td>9.6 <break/>[9.4–9.7]</td>
<td>3.8 [3.7–3.8]</td>
<td>7.4 [7.3–7.5]</td>
<td>10.7 <break/>[10.5–10.8]</td>
<td>4.2 [4.1–4.3]</td>
<td>8.6 [8.5–8.7]</td>
<td>12.4 [12.2–12.5]</td>
<td>4.8 [4.7–4.9]</td>
</tr>
<tr>
<td><bold>Standardized incidence rates per 100,000 European population<sup><xref ref-type="table-fn" rid="table-fn4-1352458511433305">***</xref></sup> [95% confidence interval]</bold></td>
<td>6,8 [6.7–6.9]</td>
<td>9,8 <break/>[9.7–10.0]</td>
<td>3,7 [3.6–3.8]</td>
<td>7.5 <break/>[7.4 – 7.6]</td>
<td>10.7 [10.6–10.9]</td>
<td>4.2 [4.1–4.3]</td>
<td>7.6 [7.5–7.7]</td>
<td>11 <break/>[10.8–11.1]</td>
<td>4.2 [4.1–4.3]</td>
<td>8.8 [8.7–8.9]</td>
<td>12.7 [12.5–12.8]</td>
<td>4.8 [4.7–4.9]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1352458511433305">
<label>*</label>
<p>CNAMTS: Caisse Nationale d’Assurance Maladie des Travailleurs Salariés; MS: Multiple Sclerosis</p>
</fn>
<fn id="table-fn3-1352458511433305">
<label>**</label>
<p>respectively the lowest (11.5%) and highest (29.0%) estimations of the underestimation rate of multiple sclerosis in Haute-Garonne according to Sagnes-Raffy et al. (Rev Epidemiol Sante Publique 2010; 58: 23–31)</p>
</fn>
<fn id="table-fn4-1352458511433305">
<label>***</label>
<p>Overall incidence rates were standardized on age and gender whereas specific gender incidence rates were standardized on age only.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section19-1352458511433305">
<title>Geographic variations</title>
<p>Mean standardized annual incidence rates for each French region are described in <xref ref-type="table" rid="table3-1352458511433305">Table 3</xref>. Standardized incidence ranged from 6.4 per 100,000 inhabitants in Provence Alpes Côte d’Azur and Rhône-Alpes, to 10.6 in Alsace.</p>
<table-wrap id="table3-1352458511433305" position="float">
<label>Table 3.</label>
<caption>
<p>Mean annual standardized Incidence on the French population of Multiple Sclerosis ‘Affection de Longue Durée’ in each region of France (2001–2007).</p>
</caption>
<graphic alternate-form-of="table3-1352458511433305" xlink:href="10.1177_1352458511433305-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Administrative region of France</th>
<th align="left" colspan="2">Covered by the CNAMTS<sup><xref ref-type="table-fn" rid="table-fn6-1352458511433305">†</xref></sup><hr/></th>
<th align="left" rowspan="2">Number of ALDs for MS<sup><xref ref-type="table-fn" rid="table-fn6-1352458511433305">†</xref></sup></th>
<th align="center" colspan="2">Overall<hr/></th>
<th align="center" colspan="2">Men<hr/></th>
<th align="center" colspan="2">Women<hr/></th>
</tr>
<tr>
<th align="left"><italic>n</italic></th>
<th align="left">%<xref ref-type="table-fn" rid="table-fn5-1352458511433305">*</xref></th>
<th align="left">MS Standardized incidence</th>
<th align="left">[95% confidence interval]</th>
<th align="left">MS Standardized incidence</th>
<th align="left">[95% confidence interval]</th>
<th align="left">MS Standardized incidence</th>
<th align="left">[95% confidence interval]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alsace</td>
<td>1,602,547</td>
<td>89.5</td>
<td>178</td>
<td>10.6</td>
<td>[10–10.2]</td>
<td>6.1</td>
<td>[5.5–6.8]</td>
<td>14.8</td>
<td>[13.8–15.7]</td>
</tr>
<tr>
<td>Lorraine</td>
<td>2,011,491</td>
<td>86.4</td>
<td>217</td>
<td>10.3</td>
<td>[9.8–10.8]</td>
<td>5.9</td>
<td>[5.3–6.5]</td>
<td>14.4</td>
<td>[13.5–15.2]</td>
</tr>
<tr>
<td>Picardie</td>
<td>1,414,355</td>
<td>85.8</td>
<td>137</td>
<td>9.5</td>
<td>[8.9–10]</td>
<td>5.2</td>
<td>[4.6–5.8]</td>
<td>13.4</td>
<td>[12.5–14.3]</td>
</tr>
<tr>
<td>Champagne Ardenne</td>
<td>1,109,343</td>
<td>82.8</td>
<td>103</td>
<td>9.1</td>
<td>[8.4–9.8]</td>
<td>4.9</td>
<td>[4.2–5.6]</td>
<td>12.9</td>
<td>[11.8–14.0]</td>
</tr>
<tr>
<td>Franche Comte</td>
<td>974,763</td>
<td>85.5</td>
<td>88</td>
<td>8.9</td>
<td>[8.2–9.6]</td>
<td>4.7</td>
<td>[4.0–5.4]</td>
<td>12.7</td>
<td>[11.5–13.8]</td>
</tr>
<tr>
<td>Centre</td>
<td>2,080,682</td>
<td>83.5</td>
<td>186</td>
<td>8.8</td>
<td>[8.3–9.3]</td>
<td>4.7</td>
<td>[4.2–5.2]</td>
<td>12.5</td>
<td>[11.7–13.3]</td>
</tr>
<tr>
<td>Nord Pas de Calais</td>
<td>3,632,529</td>
<td>90.5</td>
<td>313</td>
<td>8.3</td>
<td>[8–8.7]</td>
<td>5.3</td>
<td>[4.9–5.7]</td>
<td>11.2</td>
<td>[10.6–11.7]</td>
</tr>
<tr>
<td>Bourgogne</td>
<td>1,332,254</td>
<td>82.1</td>
<td>109</td>
<td>8.1</td>
<td>[7.5–8.7]</td>
<td>4.2</td>
<td>[3.6–4.8]</td>
<td>11.5</td>
<td>[10.6–12.4]</td>
</tr>
<tr>
<td>Bretagne</td>
<td>2,386,350</td>
<td>78.7</td>
<td>195</td>
<td>8</td>
<td>[7.6–8.4]</td>
<td>4.4</td>
<td>[3.9–4.8]</td>
<td>11.2</td>
<td>[10.5–11.9]</td>
</tr>
<tr>
<td>Basse Normandie</td>
<td>1,181,363</td>
<td>81.7</td>
<td>94</td>
<td>7.9</td>
<td>[7.3–8.5]</td>
<td>4.8</td>
<td>[4.1–5.5]</td>
<td>10.6</td>
<td>[ 9.7–11.6]</td>
</tr>
<tr>
<td>Auvergne</td>
<td>1,066,942</td>
<td>80.4</td>
<td>86</td>
<td>7.8</td>
<td>[7.2–8.4]</td>
<td>3.6</td>
<td>[3.0–4.2]</td>
<td>11.6</td>
<td>[10.6–12.6]</td>
</tr>
<tr>
<td>Corse</td>
<td>211,485</td>
<td>74.9</td>
<td>17</td>
<td>7.8</td>
<td>[6.4–9.2]</td>
<td>5.2</td>
<td>[3.6–6.8]</td>
<td>10.1</td>
<td>[7.9–12.2]</td>
</tr>
<tr>
<td>Midi Pyrénées</td>
<td>2,163,041</td>
<td>80.0</td>
<td>171</td>
<td>7.6</td>
<td>[7.2–8.0]</td>
<td>4.4</td>
<td>[4.0–4.9]</td>
<td>10.4</td>
<td>[9.7–11.1]</td>
</tr>
<tr>
<td>Haute Normandie</td>
<td>1,621,811</td>
<td>90.0</td>
<td>118</td>
<td>7.1</td>
<td>[6.6–7.6]</td>
<td>4.2</td>
<td>[3.6–4.7]</td>
<td>9.8</td>
<td>[9.0–10.6]</td>
</tr>
<tr>
<td>Ile de France</td>
<td>10,957,321</td>
<td>96.6</td>
<td>825</td>
<td>7</td>
<td>[6.8–7.2]</td>
<td>4.1</td>
<td>[3.9–4.3]</td>
<td>9.7</td>
<td>[9.4–10.0]</td>
</tr>
<tr>
<td>Languedoc Roussillon</td>
<td>1,986,402</td>
<td>80.8</td>
<td>140</td>
<td>6.9</td>
<td>[6.5–7.3]</td>
<td>3.7</td>
<td>[3.2–4.1]</td>
<td>9.7</td>
<td>[9.0–10.4]</td>
</tr>
<tr>
<td>Pays de Loire</td>
<td>2,844,424</td>
<td>84.3</td>
<td>194</td>
<td>6.7</td>
<td>[6.4–7.1]</td>
<td>3.8</td>
<td>[3.4–4.2]</td>
<td>9.4</td>
<td>[8.8–10.0]</td>
</tr>
<tr>
<td>Aquitaine</td>
<td>2,418,903</td>
<td>79.2</td>
<td>16</td>
<td>6.6</td>
<td>[6.2–7.0]</td>
<td>3.5</td>
<td>[3.1–3.9]</td>
<td>9.2</td>
<td>[8.6–9.8]</td>
</tr>
<tr>
<td>Poitou Charentes</td>
<td>1,321,368</td>
<td>77.9</td>
<td>89</td>
<td>6.6</td>
<td>[6.0–7.1]</td>
<td>3.3</td>
<td>[2.7–3.8]</td>
<td>9.4</td>
<td>[ 8.6–10.2]</td>
</tr>
<tr>
<td>PACA</td>
<td>4,182,353</td>
<td>88.7</td>
<td>276</td>
<td>6.5</td>
<td>[6.2–6.8]</td>
<td>3.6</td>
<td>[3.2–4.0]</td>
<td>9.1</td>
<td>[8.6–9.6]</td>
</tr>
<tr>
<td>Limousin</td>
<td>557,337</td>
<td>77.1</td>
<td>37</td>
<td>6.4</td>
<td>[5.6–7.2]</td>
<td>3.0</td>
<td>[2.2–3.8]</td>
<td>9.4</td>
<td>[8.1–9.1]</td>
</tr>
<tr>
<td>Rhône Alpes</td>
<td>5,190,757</td>
<td>88.0</td>
<td>341</td>
<td>6.4</td>
<td>[6.2–6.7]</td>
<td>4.0</td>
<td>[3.7–4.3]</td>
<td>8.7</td>
<td>[8.2–9.4]</td>
</tr>
<tr>
<td>Total France</td>
<td>52,449,871</td>
<td>86.7</td>
<td>4,097</td>
<td>7.6</td>
<td>[7,5–7,6]</td>
<td>4.3</td>
<td>[4.2–4.4]</td>
<td>10.5</td>
<td>[10.3–10.6]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1352458511433305">
<label>*</label>
<p>percentage of people affiliated to the CNAMTS in the general population</p>
</fn>
<fn id="table-fn6-1352458511433305">
<label>†</label>
<p>mean estimate for 2001–2007 period</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In our study, the <italic>p</italic>-value of the Potthoff–Whittinghill test was 0.02, highlighting statistically significant spatial heterogeneity. The Moran <italic>I</italic> statistic was 0.51 (<italic>p</italic>-value &lt; 10<sup>−4</sup>), which obliged us to account for spatial autocorrelation in a hierarchical Bayesian Poisson model. A geospline was retained as the most accurate model of the spatial effect. Hyperpriors were calculated according to Mollié’s method<sup><xref ref-type="bibr" rid="bibr22-1352458511433305">22</xref></sup> since the model using a geospline and such hyperpriors had the smallest DIC (3377.9). This model seemed to generate rather accurate estimations, as the relative difference between the standardized incidence and its Bayesian estimation was under 10% for almost 90% of ‘départements’.</p>
<p>Using this Bayesian approach, incidence in the north and east of France was shown to be higher than the mean French level (<xref ref-type="fig" rid="fig2-1352458511433305">Figure 2</xref>). The smoothed RRs varied from 1.12 (95% Bayesian credible interval (BCI): 1.01–1.25) in the Nord ‘département’ to 1.38 in Moselle (95% BCI: 1.23–1.53) and 1.39 (95% BCI: 1.23–1.55) in Bas Rhin. Conversely, MS incidence seemed to be lower in two regions: the ‘départements’ on the Atlantic coast and the ‘départements’ located on both sides of the Rhône River. Indeed, the smoothed RRs varied from 0.82 (95% BCI: 0.74–0.91) in Isère to 0.90 (95% BCI: 0.79–1.00) in Alpes-Maritime. We tested the north-east to south-west gradient of MS by including a trend for latitude (X) and longitude (Y), either linear (terms in X and Y) or quadratic (terms in X, Y, X<sup>2</sup>, Y<sup>2</sup>, and XY). Neither improved the fit to the data (DICs were 3449.8 and 3449.6, respectively). No significant interaction between the geographic areas and the other covariates (age, gender, and year of ALD request) was found in this study.</p>
<fig id="fig2-1352458511433305" position="float">
<label>Figure 2.</label>
<caption>
<p>Smoothed relative risk of multiple sclerosis notification rate for each ‘département’ compared with the mean French national level (both genders, Bayesian model, France, 2001–2007).</p>
</caption>
<graphic xlink:href="10.1177_1352458511433305-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section20-1352458511433305" sec-type="discussion">
<title>Discussion</title>
<p>Our study showed that French MS incidence standardized on the European population ranged between 7.6 and 8.8 per 100,000 inhabitants after accounting for MS underestimation rates. We verified that MS notification rates were stable between 2000 and 2007 despite MS diagnosis criteria change. We also showed higher annual incidence levels in north-eastern France, and lower levels on the Atlantic coast as well as in ‘départements’ in the south on both sides of the Rhône River.</p>
<p>MS geographic distribution has been shown to vary according to latitude, with increasing prevalence and incidence as distance increases from the equator.<sup><xref ref-type="bibr" rid="bibr23-1352458511433305">23</xref></sup> Recently, Alonso et al.<sup><xref ref-type="bibr" rid="bibr24-1352458511433305">24</xref></sup> showed greater incidence rates at higher latitudes in a systematic review. However, few estimates of MS incidence are available in Europe for the period 2000–2007, and these were almost all obtained on a city or regional scale. For example, the crude annual incidence in southern Europe varied between 4.1 per 100,000 for the period 1998–2002 in the city of Las Palmas (82,623 inhabitants), Spain, and 9.2 for the period 1993–2002 in Caltanissetta (60,919 inhabitants), Sicily.<sup><xref ref-type="bibr" rid="bibr9-1352458511433305">9</xref>,<xref ref-type="bibr" rid="bibr25-1352458511433305">25</xref><xref ref-type="bibr" rid="bibr26-1352458511433305"/>-<xref ref-type="bibr" rid="bibr27-1352458511433305">27</xref></sup> In northern Europe, incidence lies between 8.9 per 100,000 in Northern Ostrobothnia (386,972 inhabitants) (Finland, 2000)<sup><xref ref-type="bibr" rid="bibr28-1352458511433305">28</xref></sup> and 9.7 in Wales (429,633 inhabitants) (2007).<sup><xref ref-type="bibr" rid="bibr29-1352458511433305">29</xref></sup> In most of these studies, there were no capture–recapture techniques. Data sources were either hospital data or public health insurance systems data, or data from private and hospital neurologists or from general practitioners, but only a few studies combined these sources. Differences in population selection, in diagnosis criteria used, and in access to health care make their comparisons difficult.<sup><xref ref-type="bibr" rid="bibr30-1352458511433305">30</xref></sup></p>
<p>A study was conducted in Iceland to determine the incidence of MS among the whole population between 2002 and 2007.<sup><xref ref-type="bibr" rid="bibr11-1352458511433305">11</xref></sup> The average annual incidence was 7.6 per 100,000 inhabitants and 8.2 when adjusted to the 2000 US white population. Our results were close, but the standardization was not done according to the same population.</p>
<p>Another national study was performed by general practitioners in England<sup><xref ref-type="bibr" rid="bibr6-1352458511433305">6</xref></sup> during the period 1993–2000 using the General Practice Research Database, which included health information on about 3 million of the 47 million inhabitants of England (6%). In this study, the MS incidence rate, standardized on the world population, was 5.1 per 100,000 person-years for both genders. A higher incidence could be expected in England compared with France, given the mean latitudes of these two countries. These puzzling results could be due to a lack of representativeness of the English cohort but also to overestimation in our study. We also found a higher incidence (9.3 (8.8–9.8)) than Debouverie et al.,<sup><xref ref-type="bibr" rid="bibr15-1352458511433305">15</xref></sup> who performed the most recent and reliable study on MS incidence in Lorraine (eastern France, 2,310,376 inhabitants). The annual incidence standardized on the European population was 5.5 per 100,000 in this specific population over the 1990–2002 period. The explanation for this lower incidence could be that the Lorraine study included years during which DMTs were not available. Indeed, the standardized incidence rate in Lorraine increased in this study from 3.7 per 100,000 in 1990 to a maximum of 7.0 in 2000, which is closer to our estimation. One can also argue that we overestimated the number of new cases. However, ALD status is only granted after the diagnosis has been confirmed by a neurologist and the case ascertained by a CNAMTS doctor. This process allows a double validation of MS diagnosis and reduces the inclusion of non-definite MS. When patients benefiting from an ALD request for MS move, they inform CNAMTS of the change of address. The CNAMTS medical record then follows the patient, avoiding a duplicate ALD. Another reason for case-uncertain estimation could have been the single source of data used which may have missed (i) 13% of the French population, and (ii) 10% of MS patients with a benign form of the disease who were untreated<sup><xref ref-type="bibr" rid="bibr31-1352458511433305">31</xref></sup> and did not require ALD status. We introduced estimations of the probable under-notification rate, derived from the study performed in Haute-Garonne using a capture–recapture method.<sup><xref ref-type="bibr" rid="bibr16-1352458511433305">16</xref></sup> These under-notification rates could have been overestimated. However, the CNAMTS coverage rate in Haute-Garonne is slightly higher (89.2%) than in the overall French population, thus fewer MS cases are probably missed by the CNAMTS in this ‘département’ compared with other areas. In addition, the female to male ratio (1.05) in Haute-Garonne is similar to that calculated for the overall French population. We also showed in an earlier study that prevalence and incidence of MS among people covered by the CNAMTS in Haute-Garonne are not different from mean national levels.<sup><xref ref-type="bibr" rid="bibr2-1352458511433305">2</xref></sup> Given these arguments, we think that our estimates of incidence in France are reliable.</p>
<p>Our study also showed a higher MS incidence in north-eastern France, which is concordant with the higher MS prevalence we previously highlighted in this area. This study also revealed that MS notification rates were lower on the Atlantic coast and on both sides of the Rhône River. In addition, we used a Bayesian approach to reduce the impact of random variations between areas. We also pooled new cases of MS that were granted ALD status by the CNAMTS from 2000–2007, to obtain reliable estimates for each ‘département’. Indeed, our Bayesian model led to little difference between observed and predicted results.</p>
<p>These contrasting incidences may be related to various factors such as genetic, environmental such as amounts of sunshine,<sup><xref ref-type="bibr" rid="bibr32-1352458511433305">32</xref><xref ref-type="bibr" rid="bibr33-1352458511433305"/>-<xref ref-type="bibr" rid="bibr34-1352458511433305">34</xref></sup>or socioeconomic factors. The notification rate for MS in Paris area was similar to the national mean level, whereas we previously showed a lower than average prevalence in this area.<sup><xref ref-type="bibr" rid="bibr2-1352458511433305">2</xref></sup> This discrepancy may be related to population movements which may have contributed to a reduction in the prevalence rate. Indeed, the Paris area is known to be rather attractive for young adults, within the age of MS onset, due to the plentiful employment opportunities.<sup><xref ref-type="bibr" rid="bibr35-1352458511433305">35</xref></sup> Because of the high cost of living in the Paris area, however, the elderly tend to leave,<sup><xref ref-type="bibr" rid="bibr36-1352458511433305">36</xref></sup> leading to a prevalence decrease.</p>
<p>With an incidence of 7.6 and 8.8 per 100,000 inhabitants, we highlighted a higher MS incidence in France than previously reported using city or regional data.<sup><xref ref-type="bibr" rid="bibr12-1352458511433305">12</xref><xref ref-type="bibr" rid="bibr13-1352458511433305"/>-<xref ref-type="bibr" rid="bibr14-1352458511433305">14</xref></sup> These figures are halfway between those reported in northern and southern Europe. Moreover, we confirmed the higher incidence of MS in north-eastern France and revealed a lower incidence in south-eastern France and on the Atlantic coast.</p>
</sec>
</body>
<back>
<ack>
<p>We extend our thanks to the ARSEP foundation (French Multiple Sclerosis Research Foundation).</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sector.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare that there is no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511433305">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vukusic</surname><given-names>S</given-names></name>
<name><surname>Van Bockstael</surname><given-names>V</given-names></name>
<name><surname>Gosselin</surname><given-names>S</given-names></name>
<name><surname>Confavreux</surname><given-names>C</given-names></name>
</person-group>. <article-title>Regional variations in the prevalence of multiple sclerosis in French farmers</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2007</year>; <volume>78</volume>: <fpage>707</fpage>–<lpage>709</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511433305">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fromont</surname><given-names>A</given-names></name>
<name><surname>Binquet</surname><given-names>C</given-names></name>
<name><surname>Sauleau</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Geographic variations of multiple sclerosis in France</article-title>. <source>Brain</source> <year>2010</year>; <volume>133</volume>: <fpage>1889</fpage>–<lpage>1899</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511433305">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Midgard</surname><given-names>R</given-names></name>
<name><surname>Riise</surname><given-names>T</given-names></name>
<name><surname>Nyland</surname><given-names>H</given-names></name>
</person-group>. <article-title>Epidemiologic trends in multiple sclerosis in More and Romsdal, Norway: a prevalence/incidence study in a stable population</article-title>. <source>Neurology</source> <year>1991</year>; <volume>41</volume>: <fpage>887</fpage>–<lpage>892</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511433305">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sumelahti</surname><given-names>ML</given-names></name>
<name><surname>Tienari</surname><given-names>P</given-names></name>
<name><surname>Wikstrom</surname><given-names>J</given-names></name>
<name><surname>Palo</surname><given-names>J</given-names></name>
<name><surname>Hakama</surname><given-names>M</given-names></name>
</person-group>. <article-title>Regional and temporal variation in the incidence of multiple sclerosis in Finland 1979-1993</article-title>. <source>Neuroepidemiology</source> <year>2000</year>; <volume>19</volume>: <fpage>67</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511433305">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarasoja</surname><given-names>T</given-names></name>
<name><surname>Wikstrom</surname><given-names>J</given-names></name>
<name><surname>Paltamaa</surname><given-names>J</given-names></name>
<name><surname>Hakama</surname><given-names>M</given-names></name>
<name><surname>Sumelahti</surname><given-names>ML</given-names></name>
</person-group>. <article-title>Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years</article-title>. <source>Acta Neurol Scand</source> <year>2004</year>; <volume>110</volume>: <fpage>331</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511433305">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alonso</surname><given-names>A</given-names></name>
<name><surname>Jick</surname><given-names>SS</given-names></name>
<name><surname>Olek</surname><given-names>MJ</given-names></name>
<name><surname>Hernan</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort</article-title>. <source>J Neurol</source> <year>2007</year>; <volume>254</volume>: <fpage>1736</fpage>–<lpage>1741</lpage>.</citation>
</ref>
<ref id="bibr7-1352458511433305">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papathanasopoulos</surname><given-names>P</given-names></name>
<name><surname>Gourzoulidou</surname><given-names>E</given-names></name>
<name><surname>Messinis</surname><given-names>L</given-names></name>
<name><surname>Georgiou</surname><given-names>V</given-names></name>
<name><surname>Leotsinidis</surname><given-names>M</given-names></name>
</person-group>. <article-title>Prevalence and incidence of multiple sclerosis in western Greece: a 23-year survey</article-title>. <source>Neuroepidemiology</source> <year>2008</year>; <volume>30</volume>: <fpage>167</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511433305">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grimaldi</surname><given-names>L</given-names></name>
<name><surname>Salemi</surname><given-names>G</given-names></name>
<name><surname>Grimaldi</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>High incidence and increasing prevalence of MS in Enna (Sicily) southern Italy</article-title>. <source>Neurology</source> <year>2001</year>; <volume>57</volume>: <fpage>1891</fpage>–<lpage>1893</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511433305">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grimaldi</surname><given-names>G</given-names></name>
<name><surname>Palmeri</surname><given-names>B</given-names></name>
<name><surname>Salemi</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>High prevalence and fast rising incidence of multiple sclerosis in Caltanissetta, Sicily, Southern Italy</article-title>. <source>Neuroepidemiology</source> <year>2007</year>; <volume>28</volume>: <fpage>28</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511433305">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Granieri</surname><given-names>E</given-names></name>
<name><surname>Casetta</surname><given-names>I</given-names></name>
<name><surname>Govoni</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>The increasing incidence and prevalence of MS in a Sardinian province</article-title>. <source>Neurology</source> <year>2000</year>; <volume>55</volume>: <fpage>842</fpage>–<lpage>847</lpage>.</citation>
</ref>
<ref id="bibr11-1352458511433305">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eliasdottir</surname><given-names>OJ</given-names></name>
<name><surname>Olafsson</surname><given-names>E</given-names></name>
<name><surname>Kjartansson</surname><given-names>O</given-names></name>
</person-group>. <article-title>Incidence of multiple sclerosis in Iceland, 2002-2007: a population-based study</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>909</fpage>–<lpage>913</lpage>.</citation>
</ref>
<ref id="bibr12-1352458511433305">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moreau</surname><given-names>T</given-names></name>
<name><surname>Manceau</surname><given-names>E</given-names></name>
<name><surname>Lucas</surname><given-names>B</given-names></name>
<name><surname>Lemesle</surname><given-names>M</given-names></name>
<name><surname>Urbinelli</surname><given-names>R</given-names></name>
<name><surname>Giroud</surname><given-names>M</given-names></name>
</person-group>. <article-title>Incidence of multiple sclerosis in Dijon, France: a population-based ascertainment</article-title>. <source>Neurol Res</source> <year>2000</year>; <volume>22</volume>: <fpage>156</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr13-1352458511433305">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yaouang</surname><given-names>J</given-names></name>
<name><surname>Tron</surname><given-names>I</given-names></name>
<name><surname>Lerai</surname><given-names>E</given-names></name>
</person-group>. <article-title>Incidence of multiple sclerosis in Western France, 2000-2001</article-title>. <source>Mult Scler</source> <year>2005</year>; <volume>11</volume>: <fpage>S106</fpage>.</citation>
</ref>
<ref id="bibr14-1352458511433305">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taithe</surname><given-names>F</given-names></name>
<name><surname>Tilignac</surname><given-names>C</given-names></name>
<name><surname>Rieu</surname><given-names>L</given-names></name>
<name><surname>Murat</surname><given-names>C</given-names></name>
<name><surname>Clavelou</surname><given-names>P</given-names></name>
</person-group>. <article-title>Incidence of multiple sclerosis in Auvergne (French Country): a population-based study</article-title>. <source>Mult Scler</source> <year>2006</year>; <volume>12</volume>: <fpage>S132</fpage>.</citation>
</ref>
<ref id="bibr15-1352458511433305">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Debouverie</surname><given-names>M</given-names></name>
<name><surname>Pittion-Vouyovitch</surname><given-names>S</given-names></name>
<name><surname>Louis</surname><given-names>S</given-names></name>
<name><surname>Roederer</surname><given-names>T</given-names></name>
<name><surname>Guillemin</surname><given-names>F</given-names></name>
</person-group>. <article-title>Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France</article-title>. <source>Mult Scler</source> <year>2007</year>; <volume>13</volume>: <fpage>962</fpage>–<lpage>967</lpage>.</citation>
</ref>
<ref id="bibr16-1352458511433305">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sagnes-Raffy</surname><given-names>C</given-names></name>
<name><surname>Gourraud</surname><given-names>P-A</given-names></name>
<name><surname>Hannon</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Multiple sclerosis in Haute-Garonne: an important underestimation of case numbers</article-title>. <source>Rev Epidemiol Sante Publique</source> <year>2010</year>; <volume>58</volume>: <fpage>23</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr17-1352458511433305">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Breslow</surname><given-names>N</given-names></name>
<name><surname>Day</surname><given-names>N</given-names></name>
</person-group>. <article-title>Statistical methods in cancer research. Volume II – The design and analysis of cohort studies</article-title>. <source>IARC Sci Publ</source> <year>1987</year>; <volume>82</volume>: <fpage>1</fpage>–<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr18-1352458511433305">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Potthoff</surname><given-names>R</given-names></name>
<name><surname>Whittinghill</surname><given-names>M</given-names></name>
</person-group>. <article-title>Testing for homogeneity: the binomial and multinomial distributions</article-title>. <source>Biometrika</source> <year>1966</year>; <volume>53</volume>: <fpage>167</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr19-1352458511433305">
<label>19.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Cliff</surname><given-names>A</given-names></name>
<name><surname>Ord</surname><given-names>J</given-names></name>
</person-group>. <article-title>Spatial processes: Models and applications</article-title>. <publisher-loc>London</publisher-loc>: <publisher-name>Taylor &amp; Francis</publisher-name>, <year>1981</year>, p. <fpage>266</fpage>.</citation>
</ref>
<ref id="bibr20-1352458511433305">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pascutto</surname><given-names>C</given-names></name>
<name><surname>Wakefield</surname><given-names>JC</given-names></name>
<name><surname>Best</surname><given-names>NG</given-names></name>
<etal/>
</person-group>. <article-title>Statistical issues in the analysis of disease mapping data</article-title>. <source>Statist Med</source> <year>2000</year>; <volume>19</volume>: <fpage>2493</fpage>–<lpage>2519</lpage>.</citation>
</ref>
<ref id="bibr21-1352458511433305">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spiegelhalter</surname><given-names>D</given-names></name>
<name><surname>Best</surname><given-names>N</given-names></name>
<name><surname>Carlin</surname><given-names>B</given-names></name>
<name><surname>Van der Linde</surname><given-names>A</given-names></name>
</person-group>. <article-title>Bayesian measures of model complexity and fit (with discussion)</article-title>. <source>J R Stat Soc</source> <year>2002</year>; <volume>64</volume>: <fpage>583</fpage>–<lpage>639</lpage>.</citation>
</ref>
<ref id="bibr22-1352458511433305">
<label>22.</label>
<citation citation-type="thesis">
<person-group person-group-type="author">
<name><surname>Mollie</surname><given-names>A</given-names></name>
</person-group>. <source>Représentation géographique des taux de mortalité: modélisation spatiale et méthodes bayésiennes</source>. <comment>PhD Thesis</comment>, <publisher-name>Universite Paris 6, France</publisher-name>, <year>1990</year>.</citation>
</ref>
<ref id="bibr23-1352458511433305">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurtzke</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Epidemiologic contributions to multiple sclerosis: an overview</article-title>. <source>Neurology</source> <year>1980</year>; <volume>30</volume>: <fpage>61</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr24-1352458511433305">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alonso</surname><given-names>A</given-names></name>
<name><surname>Hernan</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Temporal trends in the incidence of multiple sclerosis: a systematic review</article-title>. <source>Neurology</source> <year>2008</year>; <volume>71</volume>: <fpage>129</fpage>–<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr25-1352458511433305">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aladro</surname><given-names>Y</given-names></name>
<name><surname>Alemany</surname><given-names>M</given-names></name>
<name><surname>Perez-Vieitez</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence and incidence of multiple sclerosis in Las Palmas, Canary Islands, Spain</article-title>. <source>Neuroepidemiology</source> <year>2005</year>; <volume>24</volume>: <fpage>70</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr26-1352458511433305">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Granieri</surname><given-names>E</given-names></name>
<name><surname>Economou</surname><given-names>N</given-names></name>
<name><surname>De Gennaro</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Multiple sclerosis in the province of Ferrara: evidence for an increasing trend</article-title>. <source>J Neurol</source> <year>2007</year>; <volume>12</volume>: <fpage>1642</fpage>–<lpage>1648</lpage>.</citation>
</ref>
<ref id="bibr27-1352458511433305">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Granieri</surname><given-names>E</given-names></name>
<name><surname>Monaldini</surname><given-names>C</given-names></name>
<name><surname>De Gennaro</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Multiple sclerosis in the Republic of San Marino: a prevalence and incidence study</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>325</fpage>–<lpage>329</lpage>.</citation>
</ref>
<ref id="bibr28-1352458511433305">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krökki</surname><given-names>O</given-names></name>
<name><surname>Bloigu</surname><given-names>R</given-names></name>
<name><surname>Reunanen</surname><given-names>M</given-names></name>
<name><surname>Remes</surname><given-names>A</given-names></name>
</person-group>. <article-title>Increasing incidence of multiple sclerosis in women in Northern Finland</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>133</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr29-1352458511433305">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirst</surname><given-names>C</given-names></name>
<name><surname>Ingram</surname><given-names>G</given-names></name>
<name><surname>Pickersgill</surname><given-names>T</given-names></name>
<name><surname>Swingler</surname><given-names>R</given-names></name>
<name><surname>Compston</surname><given-names>D</given-names></name>
<name><surname>Robertson</surname><given-names>N</given-names></name>
</person-group>. <article-title>Increasing prevalence and incidence of multiple sclerosis in south east Wales</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2009</year>; <volume>80</volume>: <fpage>386</fpage>–<lpage>391</lpage>.</citation>
</ref>
<ref id="bibr30-1352458511433305">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pugliatti</surname><given-names>M</given-names></name>
<name><surname>Rosati</surname><given-names>G</given-names></name>
<name><surname>Carton</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>The epidemiology of multiple sclerosis in Europe</article-title>. <source>Eur J Neurol</source> <year>2006</year>; <volume>13</volume>: <fpage>700</fpage>–<lpage>722</lpage>.</citation>
</ref>
<ref id="bibr31-1352458511433305">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sekkat</surname><given-names>Z</given-names></name>
<name><surname>Ongagna</surname><given-names>J</given-names></name>
<name><surname>Barady</surname><given-names>B</given-names></name>
<name><surname>Collongues</surname><given-names>N</given-names></name>
<name><surname>De Seze</surname><given-names>J</given-names></name>
</person-group>. <article-title>Frequency and non treatment’s reasons for multiple sclerosis patients</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>S122</fpage>.</citation>
</ref>
<ref id="bibr32-1352458511433305">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ebers</surname><given-names>GC</given-names></name>
</person-group>. <article-title>Environmental factors and multiple sclerosis</article-title>. <source>Lancet Neurol</source> <year>2008</year>; <volume>7</volume>: <fpage>268</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr33-1352458511433305">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beretich</surname><given-names>B</given-names></name>
<name><surname>Beretich</surname><given-names>T</given-names></name>
</person-group>. <article-title>Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>891</fpage>–<lpage>898</lpage>.</citation>
</ref>
<ref id="bibr34-1352458511433305">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orton</surname><given-names>SM</given-names></name>
<name><surname>Wald</surname><given-names>L</given-names></name>
<name><surname>Confavreux</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Association of UV radiation with multiple sclerosis prevalence and sex ratio in France</article-title>. <source>neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>425</fpage>–<lpage>431</lpage>.</citation>
</ref>
<ref id="bibr35-1352458511433305">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baccaini</surname><given-names>B</given-names></name>
</person-group>. <article-title>Inter regional migration flows in France over the last fifty years</article-title>. <source>Population</source> <year>2007</year>; <volume>1</volume>: <fpage>139</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr36-1352458511433305">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fesseau</surname><given-names>M</given-names></name>
<name><surname>Passeron</surname><given-names>W</given-names></name>
<name><surname>Verone</surname><given-names>M</given-names></name>
</person-group>. <article-title>Les prix plus élevés en Ile de France qu’en province</article-title>. <source>Insee première</source> <year>2008</year>; <volume>1210</volume>: <fpage>1</fpage>–<lpage>4</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>